Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666632 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP2A6PSMB5PDE3BPDE3A | |
| SCHEMBL14405531 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2A6PDE3BPDE3AKDM4E | |
| SCHEMBL18378968 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP2A6PSMB5PDE3BPDE3A | |
| SCHEMBL17309719 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP2A6PSMB5PDE3BPDE3A | |
| SCHEMBL4764348 | 0.80 | KDM4E (0.55) | CYP1A2KDM4EPSMD14COPS5CCR1 | |
| SCHEMBL23674641 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP2A6PSMB5PDE3BPDE3A | |
| SCHEMBL5215594 | 0.80 | KDM4E (0.53) | CYP1A2KDM4EPSMD14COPS5CCR1 | |
| SCHEMBL21064338 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP2A6PSMB5PDE3BPDE3A | |
| SCHEMBL21893491 | 0.80 | PDGFRB (0.51) | CYP1A2PSMB5KDM4EPSMD14COPS5 | |
| SCHEMBL5545382 | 0.80 | CYP1A2 (0.50) | CYP1A2KDM4EPSMD14COPS5CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111184-A1 | SUBSTITUTED TETRAHYDROQUINOLINE AND TETRAHYDROQUINOXALINE HERBICIDES | FMC CORPORATION (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-1857521-B2 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEM CORP (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-7662478-B2 | Polymer and polymer light-emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090066223-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080103278-A1 | NEW POLYMER AND POLYMER LIGHT-EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED | 2008-05-01 | — | — | US | disclosed |
| EP-1857521-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | Mitsubishi Chemical Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-0847389-A4 | PROCESS FOR PREPARING QUINOLINE BASES | REILLY IND INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0847389-A1 | PROCESS FOR PREPARING QUINOLINE BASES | REILLY INDUSTRIES, INC. (US) | 1998-06-17 | — | — | EP | disclosed |
| US-5700942-A | Process for preparing quinoline bases | REILLY INDUSTRIES, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| WO-1997003051-A1 | PROCESS FOR PREPARING QUINOLINE BASES | REILLY INDUSTRIES, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103278-A1 | NEW POLYMER AND POLYMER LIGHT-EMITTING DEVICE USING THE SAME | CRY1, ARCN1, CORO1A | CYP1A2 2208/4885CYP2A6 3039/4885PSMB5 1952/4885 |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | CYP1A2 888/4885CYP2A6 787/4885PSMB5 1860/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CYP1A2 1655/4885CYP2A6 1111/4885PSMB5 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.